1. Principal investigator in Institutional Funding Program for Research and Development – major research project (Grant no.: IFPRC-196-141-2020) titled ‘Screening and validation of new antidiabetic drugs for prophylactic and therapeutic role in neurological disorders’ funded by the Vice Presidency of Graduate Studies and Scientific Research, King Abdulaziz University, Jeddah, Saudi Arabia (Proposed funding amount: $80,000)
2. Principal investigator in Institutional Funding Program for Research and Development - research program path (Grant no.: IFPHI-124-141-2020) titled ‘Gene-disease association of Galectin-1 using random walk with restart algorithm and its prioritization’ funded by the Vice Presidency of Graduate Studies and Scientific Research, King Abdulaziz University, Jeddah, Saudi Arabia (Funded amount: $53,000).
3. Principal investigator in Knowledge Excellence Program (Grant no. KEP-1-141-41) titled ‘Investigation of protein biomarkers as potential therapeutic agents of neurodegenerative disorder patients in Saudi Arabia’ funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Saudi Arabia (Funded amount: $21,000).
4. Principal investigator in Knowledge Excellence Program (Grant no.: KEP-2-141-38) titled ‘Understanding the molecular and behavioral mechanism of effects of newest antidiabetic drugs in dementia patients’ funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Saudi Arabia (Funded amount: $24,000).
5. Principal investigator in High Quality/Impact Research Publication Initiative (Grant no.: HIQI-49-2019) titled ‘Structural modeling and measurement of brain volume’ funded by the Vice Presidency for Graduate Studies and Scientific Research, Research and Development Office, King Abdulaziz University, Jeddah, Saudi Arabia (Funded amount: $29,000).
6. Principal investigator in General Research Program (Grant no.: G -1436 - 141 - 412) titled ‘Studies on immunological, oxidative burst and degranulation properties of a galectin-1 purified from goat (Capra hircus) heart’ funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Saudi Arabia (Funded amount: $21,000).
7. Principal investigator in Knowledge Excellence Program (Grant no.: KEP-2-141-40) titled ‘Understanding the behavioral and molecular mechanism of effects of antipsychotic and antidiabetic drugs in pyschotic patients with diabetic condition’ funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Saudi Arabia (Funded amount: $21,000).
8. Co-investigator in Institutional Funding Program for Research and Development - research program path (Grant no.: IFPHI-285-130-2020) titled ‘Analysis of interaction between odorant receptors and flexible spike of SARS CoV-2- key to loss of smell’ funded by the Vice Presidency of Graduate Studies and Scientific Research, King Abdulaziz University, Jeddah, Saudi Arabia ($53,000).
9. Co-investigator in General Research Program (Grant no. G: 418-141-1438) titled ‘Novel drug designing targeting key signalling protein PI3K kinases to combat cancer in Saudi Arabia’ funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Saudi Arabia (Funded amount: $11,000).
10. Co-investigator in Research Project (Grant no.: 12-BIO-3082-03) titled ‘Structural and functional studies of lactoperoxidase, an antimicrobial protein from camel milk’ funded by Strategic Technologies Research Program, King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia (Funded amount: $445,000).
11. Co-investigator in General Research Program (Grant no.: G-1435-141-528) titled ‘A putative associations of Interleukin-1β and interleukin-10 gene polymorphism with coronary artery diseases in Saudi population’ funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Saudi Arabia (Funded amount: $39,000).
1. Ashraf GM*, Chatzichronis S, Alexiou A, Firdousi G, Kamal MA, Ganash M. Dietary alterations in impaired mitochondrial dynamics due to neurodegeneration. Frontiers in Aging Neuroscience (2022) 14:893018. [Impact Factor: 5.702]
2. Mamun AA, Uddin MS, Perveen A, Jha NK, Alghamdi BS, Jeandet P, Zhang HJ, Ashraf GM*. Inflammation-targeted nanomedicine against brain cancer: from design strategies to future developments. Seminars in Cancer Biology (2022) 86(2):101-116 [Impact Factor: 17.012]
3. Ashraf GM*,, Chatzichronis S, Alexiou A, Kyriakopoulos N, Alghamdi BS, Tayeb HO, Alghamdi JS, Khan W, Jalal MB, Atta HM. BrainFD: measuring the intracranial brain volume with fractal dimension. Frontiers in Aging Neuroscience (2021) 13:765185. [Impact Factor: 5.750]
4. Ashraf GM*, Alghamdi BS, Alshehri FS, Alam MZ, Tayeb HO, Tarazi FI. Empagliflozin effectively attenuates olanzapine-induced body weight gain in female Wistar rats. Frontiers in Pharmacology (2021) 12:578716. [Impact Factor: 5.810]
5. Ashraf GM*, Alghamdi BS, Alshehri FS, Alam MZ, Tayeb HO, Tarazi FI. Standardizing the effective correlated dosage of Olanzapine and Empagliflozin in female Wistar rats. Current Gene Therapy (2021) 21(1):53-59. [Impact Factor: 4.391]
6. Uddin MS, Mamun AA, Alghamdi BS, Tewari D, Jeandet P, Sarwar MS, Ashraf GM*. Epigenetics of glioblastoma multiforme: from molecular mechanisms to therapeutic approaches. Seminars in Cancer Biology (2021) 83:100-120. [Impact Factor: 17.012]
7. Uddin MS, Tewari D, Mamun AA, Kabir MT, Niaz K, Wahed MIW, Barreto GE, Ashraf GM*. Circadian and sleep dysfunction in Alzheimer's disease. Ageing Research Reviews (2020) 60:101046. [Impact Factor: 10.895]
8. Ullah MF, Ahmad A, Bhat SH, Abu-Duhier FM, Barreto GE, Ashraf GM*. Impact of sex differences and gender specificity on behavioral characteristics and pathophysiology of neurodegenerative disorders. Neuroscience and Biobehavioral Reviews (2019) 102:95-105. [Impact Factor: 9.052]
9. Ashraf GM*, Baeesa SS. Investigation of Gal-3 expression pattern in serum and cerebrospinal fluid of patients suffering from neurodegenerative disorders. Frontiers in Neuroscience (2018) 12:430. [Impact Factor: 5.152]
